Psychedelics – News and Features

The use of the active ingredient 3,4-methylenedioxy-N-methylamphetamine (MDMA), commonly known as "ecstasy", to support psychotherapy for mental illnesses such as post-traumatic stress disorder is being discussed worldwide.

Research has found that a new tablet form of ketamine has shown promise in treating severe depression, offering a potential alternative to existing clinic-based treatments that can be expensive and lacking in convenience for some patients.

Older individuals who self-reported using psychedelics had fewer depressive symptoms and higher cognitive performance, a new study, published in Gerontology and Geriatric Medicine, has found.

Lifetime LSD use is associated with a higher likelihood of severe psychological distress after losing one’s job. The new work used data from the 2008-2019 National Survey on Drug Use and Health on the United States civilian, non-institutionalized population.

Oregon is first in the nation to provide state-regulated access to magic mushrooms; study is first to identify measures for high-quality services.

To learn more about the FDA's pending decision on MDMA-assisted therapy for PTSD, Technology Networks interviewed Dr. Sam Clark, CEO of Terran Biosciences, who leads one of the industry’s largest psychedelic development programs.

In preclinical experiments, researchers optimized a targeted drug delivery method where nanocarriers release their cargo at exactly the desired location.

Interest in a potentially harmful "magic mushroom" is skyrocketing. Amanita muscaria is being marketed as having similar health benefits to psilocybin, despite being completely different.

The first participant in a new psychedelic study has received a dose of a synthetic formulation of 5-MeO-DMT. The study is set to evaluate its neurophysiological effects on the human brain and perceived “mystical experiences.”

Researchers at the University of Colorado Anschutz Medical Campus have established a new framework for understanding how classic antidepressants work in treating major depressive disorder (MDD).